| Date | Title | Description |
| 18.09.2026 | El liderazgo emprendedor e inversor español con dimensión internacional se da cita en Sevilla la próxima semana en la quinta edición de Al Andalus Innovation Venture | La quinta edición de Al Andalus Innovation Venture congregará en Sevilla los días 22 y 23 de septiembre a más de 3.000 participantes, procedentes de toda España y desde otros países. Es la gran cita anual de dimensión nacional e internacion... |
| 17.09.2026 | The Melanoma Research Foundation Launches its Annual Los Angeles 5K Fundraiser with a Goal of $100,000 in Support of Melanoma Research, Education and Advocacy | The Melanoma Research Foundation (MRF) is excited to announce the next stop in its annual Miles for Melanoma 5K series, uniting melanoma patients, survivors, caregivers and supporters across the Los Angeles community. This year we will be h... |
| 02.09.2026 | С первого дубля | С первого дубля Иностранные инновации в фармацевтике появятся в стране через российские копии
С марта 2026 года Минздрав одобрил клинические исследования (КИ) как минимум семи инновационных разработок иностранных компаний, которые только не... |
| 27.08.2026 | Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ... |
| 20.08.2026 | Bristol Myers Squibb Partners with Chai Discovery for AI Antibody Design | What You Should Know
Chai Discovery announced a strategic biopharmaceutical collaboration with Bristol Myers Squibb (BMS) to advance the discovery and engineering of therapeutic antibodies using artificial intelligence.
Bristol Myers Squibb... |
| 18.08.2026 | Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer | Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer
Tue, Aug 18, 2026 10:35 CET Report this content
OSLO, Norway, 18 August 2026 – Lytix Biopharma ASA (“Lytix” or the “Com... |
| 14.08.2026 | Pharmaceuticals Market Trends: Innovation, Rising Healthcare Demand, and Advanced Therapies Driving Growth | The pharmaceuticals market is witnessing strong growth as rising healthcare needs, increasing disease prevalence, expanding access to medicines, and continuous innovation in drug development drive global demand. Pharmaceutical products play... |
| 12.08.2026 | Silent Cancer Therapeutics Market Size to Reach USD 36.52 Billion by 2035, Driven by Precision Oncology and Advanced Cancer Therapies | Overview
According to DataM Intelligence, the global silent cancer therapeutics market size was valued at USD 15.86 billion in 2025 and is forecast to reach USD 36.52 billion by 2035, expanding at a CAGR of 8.7% during 2026 to 2035. The mar... |
| 06.08.2026 | Prothena Reports Second Quarter 2026 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the second quarter and... |
| 06.08.2026 | AstraZeneca may buck a decade of pharma strategy to buy U.S. scale | Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb’s U.S.-centric business, but at the cost of slower growth and integration risk.
The reports had the industr... |
| 05.08.2026 | Pharma Giants Eye Colossal Merger: AstraZeneca and Bristol Myers Squibb in $400 Billion Talks | AstraZeneca and Bristol Myers Squibb reportedly discuss a $400 billion pharmaceutical megamerger. This potential tie-up would reshape the industry. The news sent AstraZeneca shares down, puzzling market analysts. Many question the strategic... |
| 04.08.2026 | Акции AstraZeneca упали на 9% после сообщений о сделке с BMS | Акции AstraZeneca упали на 9% после сообщений о сделке с BMS Инвесторы не увидели очевидных преимуществ возможного объединения
Инвесторы британо-шведской фармкомпании AstraZeneca негативно восприняли сообщения о возможной покупке американск... |
| 03.08.2026 | AstraZeneca slides after report of Bristol Myers merger talks leaves analysts ‘perplexed’ | AstraZeneca is reportedly in talks with U.S. peer Bristol Myers Squibb over a megadeal.
If completed, a combined company could be valued at roughly roughly $400 billion.
Analysts were puzzled by both the news itself, as well as the timing o... |
| 03.08.2026 | Stocks making the biggest moves premarket: Alibaba, Bristol-Myers Squibb, eBay & more | - |
| 03.08.2026 | Astrazeneca explores $400bn megadeal with US rival | Astrazeneca is exploring a $400bn (£300bn) merger with US rival Bristol Myers Squibb, in a deal that would create one of the world’s largest pharmaceutical groups.
The FTSE 100 giant has held talks with the US group in recent months about a... |
| 03.08.2026 | CNBC Daily Open: Back to the negotiating table | Trump said negotiations with Iran will begin Monday after he held off on new strikes.
A U.K. maritime agency reported an explosion in close proximity to a vessel near Khasab, Oman.
Ukrainian officials fear a Russian assault on energy infras... |
| 03.08.2026 | Stocks making the biggest moves midday: Amazon, Corning, CoreWeave, Bristol Myers & more | - |
| 03.08.2026 | Dow hits fresh record as oil prices tumble | NEW YORK: Oil prices slumped and stocks mostly rose Monday (Aug 3) after US President Donald Trump insisted negotiations with Iran were ongoing despite Tehran's denials.
Crude futures slid more than four per cent as markets brushed aside Ir... |
| 03.08.2026 | CNBC Daily Open: Markets exhale as Trump steps back, OPEC+ steps up | Trump canceled a planned attack on Iran, saying the “perimeters of a deal” had been agreed.
OPEC+ approved a September output increase of about 188,000 barrels a day.
Oil prices retreated sharply, unwinding gains built on months of conflict... |
| 03.08.2026 | Much 'to do' about yen intervention | Previous
Japan's Finance Minister Satsuki Katayama speaks to the media about the U.S.-Japan joint forex action upon her arrival at the Finance Ministry in Tokyo, Japan, August 3, 2026. REUTERS/Issei Kato TPX IMAGES OF THE DAY
A man walks pa... |
| 03.08.2026 | Ratio Therapeutics Raises $70M in Series C Funding | Ratio Therapeutics, a Boston, MA-based provider of a radiopharmaceutical platform developing targeted cancer treatments, raised $70M in Series C funding.
Backers included Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Managem... |
| 03.08.2026 | Британская AstraZeneca обсуждала с американской Bristol Myers Squibb слияние стоимостью почти $400 млрд | Британская фармацевтическая компания AstraZeneca и американская Bristol Myers Squibb (BMS) провели предварительные переговоры о возможном слиянии, которое может привести к созданию одного из крупнейших производителей лекарств в мире с совок... |
| 03.08.2026 | Astrazeneca share price tumbles on $400bn megamerger talks | Astrazeneca’s share price slumped sharply on Monday as investors baulked at a potential $400bn megamerger with US rival Bristol Myers Squibb.
Shares in the UK drugmaker slid six per cent in early trading to 11,866p after the Financial Times... |
| 02.08.2026 | AstraZeneca Targets $400B Bristol Myers Squibb Merger Twelve Years After Spurning Pfizer | By Joshua Mitchell
Published: Aug 02 2026, 5:39 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 02.08.2026 | Stock futures rise in first trading day of August as oil prices slide: Live updates | U.S. equity futures rose early Monday as investors awaited the July jobs report and another busy week of earnings to kick off August trading.
Futures tied to the Dow Jones Industrial Average rallied 333 points, or 0.63%. S&P 500 futures... |
| 02.08.2026 | AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports | UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times.
The megadeal would be one of the largest in history, creating a combined compa... |
| 30.07.2026 | Qureight Secures $20M for AI-Powered Clinical Trials | Qureight secured $20 million in Series B funding. Molten Ventures led the round, joined by existing investors. This capital fuels Qureight's AI-powered imaging platform. It targets lung and heart clinical trials. The technology accelerates ... |
| 30.07.2026 | Daily Stock Market Live
S&P 500 closes higher Friday as Amazon surges; Dow posts fourth straight winning month: Live updates | The major averages were markedly higher Friday, the last trading session in July, as investors looked past rising bond yields and Amazon shares jumped.
The Nasdaq Composite rose 1% to end at 25,373.85, while the S&P 500 added 0.7% to cl... |
| 29.07.2026 | Qureight Raises $20M for AI-powered Lung and Heart Clinical Trials | Qureight just raised $20 million to fix how to read a chest scan. The Cambridge company builds AI imaging tools for lung and heart clinical trials, and its Series B was led by Molten Ventures, with backers Hargreave Hale AIM VCT, XTX Ventur... |
| 27.07.2026 | Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o... |
| 24.07.2026 | Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 24, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therap... |
| 20.07.2026 | Bristol Myers buys Nvidia's latest AI computing system for drug research | Previous
NVIDIA logo and word "Artificial Intelligence" are seen in this illustration taken July 20, 2026. REUTERS/Dado Ruvic/Illustration
Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration ... |
| 15.07.2026 | Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada | MISSISSAUGA, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada a... |
| 11.07.2026 | Beeline Medicines Closes $426.3M Series A, Accelerates Autoimmune Drug Development | Beeline Medicines, a clinical-stage biotechnology firm in Stamford, CT, announced a significant Series A extension. It secured an additional $126.3 million. This pushed its total Series A funding to an impressive $426.3 million. The capital... |
| 09.07.2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| 08.07.2026 | Beeline Medicines Raises $426.3 Million Series A To Advance Autoimmune And Inflammatory Disease Portfolio | Beeline Medicines announced the closing of a $126.3 million Series A extension. The new funding brings the company’s total Series A financing round to $426.3 million. The extension adds to Beeline Medicines’ previously announced $300 millio... |
| 08.07.2026 | The Blueprint for Better Lung Cancer Screening | Originally published on Devex.com
By Devex Partnerships
Listen on Spotify, Apple Podcasts, Soundcloud, YouTube, or search "Devex" in your favorite podcast app.
NORTHAMPTON, MA / ACCESS Newswire / July 8, 2026 / Kentucky has the hi... |
| 08.07.2026 | Beeline Medicines Inks Upsized Series A of $426.3M |
BOSTON, MA, Beeline Medicines Corporation, a clinical-stage biotechnology company, announced the closing of a $126.3 million Series A extension.
>> Click here for more funding data on Beeline Medicines
>> To export Beeline Medi... |
| 06.07.2026 | Beeline Medicines Raises $126.3M in Series A Extension Funding | Beeline Medicines Corporation, a Stamford, CT-based clinical-stage biotechnology company focused on developing and delivering precision therapies for people with autoimmune and inflammatory diseases, raised $126.3M in Series A extension fun... |
| 26.06.2026 | Seven Boson Group Launches Sovereign AI Decision Intelligence Service for the AGI Era | Ltd. today announced the launch of its Sovereign AI Decision Intelligence software and services, enabling nations to own, deploy, and govern frontier AI without dependency on foreign providers.
The launch arrives at a pivotal moment: on Jun... |
| 25.06.2026 | Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI | More than 450 executives from 100+ leading life sciences organizations gathered in Princeton, NJ to move agentic AI past the proof-of-concept stage
Founder and CEO Jaswinder "Jassi" Chadha challenged the industry with a counterint... |
| 22.06.2026 | BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology | BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic’s BrainTransporter™ technology
Mon, Jun 22, 2026 07:32 CET Report this content
Stockholm, Sweden, June 22, 2026 – BioArctic AB (publ) (Nas... |
| 16.06.2026 | Cellares Secures $327M, Revolutionizing Cell Therapy Manufacturing Globally | Cellares closed its Series D funding at $327 million, backed by ARK Invest, Prime Radiant Partners, and other major investors. This capital drives global expansion of its automated cell therapy manufacturing. The IDMO model and Smart Factor... |
| 16.06.2026 | Colorado receives FDA permission to import cheaper drugs — including Ozempic — from Canada | Getting your Trinity Audio player ready...
Colorado finally has federal permission to start importing cheaper prescription drugs from Canada, but the state may not have any sellers to work with.
Lawmakers passed a bill in 2019 that directed... |
| 15.06.2026 | Cellares Expands Series D To $327 Million With $50 Million Investment From Prime Radiant Partners | Cellares announced that Prime Radiant Partners has invested $50 million in the company’s Series D financing, bringing the total round to $327 million and providing additional capital to support commercial operations, a planned initial publi... |
| 11.06.2026 | Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ther... |
| 09.06.2026 | Открытое использование (public domain): когда истекает патент и как работать с общественным достоянием | Патент — это временная монополия. Государство даёт изобретателю исключительное право на коммерческое использование технологии в обмен на ее публичное раскрытие. Когда срок действия данного права истекает, технология переходит в общественное... |
| 09.06.2026 | Cellares Receives $20M Investment from ARK Invest | Cellares, a South San Francisco, CA-based Integrated Development and Manufacturing Organization (IDMO), received a $20m investment from ARK Invest.
ARK Invest joined the company’s Series D financing, bringing the total Series D to $277m. AR... |
| 05.06.2026 | Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing | OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milesto... |
| 31.05.2026 | A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China | An experimental lung cancer drug from Akeso and Summit Therapeutics improved survival in the Harmoni-6 Phase 3 trial conducted in China, according to results being presented at the American Society of Clinical Oncology annual meeting.
Calle... |
| 28.05.2026 | Meta Advises Eylsia Nicolas on India BookKards Budget as Her Biography Pre‑Release Highlights Surging Global Demand for Her Music | North Palm Beach, Florida, United States; Mumbai, Maharashtra, India
Recording artist, inventor, and digital publishing innovator Eylsia Nicolas has pre‑released her biography Not Like Anyone Else as part of her BookKards pilot in India, wi... |
| 23.05.2026 | The Melanoma Research Foundation Launches its Annual Denver 5K Fundraiser with a Goal of $100,000 in Support of Melanoma Research, Education and Advocacy | The Melanoma Research Foundation (MRF) is excited to announce the next stop in its annual Miles for Melanoma 5K series, uniting melanoma patients, survivors, caregivers and supporters across the Denver community. This year we will be hostin... |
| 20.05.2026 | Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery | Previous
FILE PHOTO: Anthropic logo is seen in this illustration taken May 20, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/B... |
| 16.05.2026 | CU Boulder sees 11th startup reach $1 billion unicorn status | Getting your Trinity Audio player ready...
Forge Nano, an advanced materials company and University of Colorado Boulder startup, has reached a $1.6 billion valuation, making it CU Boulder’s 11th “unicorn,” or a privately held company with a... |
| 12.05.2026 | Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology | Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide
Agreements include 13 programs with the potential to address significant unmet patient needs an... |
| 12.05.2026 | Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer | European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS
Dr. Myint, a hematology lead... |
| 07.05.2026 | Prothena Reports First Quarter 2026 Financial Results and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2... |
| 07.05.2026 | 4D Path Announces Strategic Financing And Two New Board Appointments | 4D Path, a company personalizing cancer care through a physics-informed approach to predict tumor response to therapy, has announced the first close of a strategic financing round alongside the appointment of two seasoned healthcare executi... |
| 05.05.2026 | Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent | Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, a... |
| 01.05.2026 | Jason Chambers Teams Up with the Melanoma Research Foundation to #GetNaked for Melanoma Awareness Month | The Melanoma Research Foundation (MRF) is pleased to announce the launch of its annual award-winning #GetNaked campaign recognizing the melanoma patient community during Melanoma Awareness Month. In 2026, the MRF is joined by Superyacht Cap... |
| 29.04.2026 | Eylsia Nicolas Partners with Meta India to Launch AI Adaptive Digital Publishing Platform Powered by Micro Payments | North Palm Beach, Florida, United States; Mumbai, Maharashtra, India
Global recording artist and inventor Eylsia Nicolas has selected Meta India as her advisory partner for the launch of BookKards, a patented digital publishing format that ... |
| 27.04.2026 | Beeline Medicines Ignites Precision Immunology with $300M Funding | Beeline Medicines secured $300 million in Series A funding, spearheaded by Bain Capital. This biotech now officially launches, poised to revolutionize treatment for autoimmune and inflammatory diseases. Its foundation rests on five clinical... |
| 22.04.2026 | Beeline Medicines: $300 Million Series A Launches Precision Immunology Biotech With Broad Pipeline | Beeline Medicines officially launched with $300 million in Series A financing led by Bain Capital, positioning the company to develop next-generation precision therapies for autoimmune and inflammatory diseases.
Originally formed in July 20... |
| 16.04.2026 | Beeline Medicines Raises $300M in Series A Financing | Beeline Medicines, a Stamford, Connecticut-based clinical-stage biotechnology company, raised $300m in Series A financing.
The round was led by Bain Capital.
The company intends to use the funds to advance its pipeline.
Beeline Medicines is... |
| 07.04.2026 | Corporate Vision and Trade Confrontation: The Shifting U.S. Economic Narrative | Motorola Solutions CEO Greg Brown earns top honors, lauded for transforming the company into a global public safety and security technology leader. His strategic vision and operational prowess drove exceptional growth and innovation. Meanwh... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 02.04.2026 | Trump unveils 100% tariff on some patented drugs on ‘Liberation Day’ anniversary | Getting your Trinity Audio player ready...
By WYATTE GRANTHAM-PHILIPS, AP Business Writer
NEW YORK (AP) — President Donald Trump signed an executive order Thursday that could slap long-threatened pharmaceutical tariffs of up to 100% on some... |
| 30.03.2026 | Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of... |
| 19.03.2026 | Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 19, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody thera... |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 02.03.2026 | Canva Forges Ahead Amidst AI Market Shift | Canva navigates a challenging software market. Wall Street punishes tech stocks. AI concerns drive investor apprehension. Major competitor Adobe faces significant stock declines. Canva responds with strategic acquisitions. It buys Cavalry, ... |
| 27.02.2026 | Gilead Dominates Cell Therapy: $7.8 Billion Arcellx Acquisition Seals Future | Gilead Sciences acquired Arcellx for up to $7.8 billion. This landmark acquisition secures full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. Anito-cel await... |
| 27.02.2026 | Prothena Announces up to $100 Million Share Repurchase Plan | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized ... |
| 26.02.2026 | NYSE Content Update: 'Patty' at Center of Burger King's New BK Assistant AI Solution | NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE P... |
| 25.02.2026 | NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options | NYSE issues a pre-market daily advisory direct from the trading floor.
NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE P... |
| 23.02.2026 | Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and... |
| 23.02.2026 | Фармгигант из США Gilead заплатит до $7,8 млрд за разработчика CAR-T - терапии Arcellx | Gilead покупает разработчика противораковых препаратов Arcellx за сумму до $7,8 млрд. Gilead согласилась приобрести Arcellx в сделке стоимостью $7,8 млрд, поскольку фармкомпания стремится добавить в свой портфель CAR-T-клеточную терапию про... |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 20.02.2026 | With Trump’s ‘reciprocal’ tariffs struck down, here are the industries still facing higher rates | President Donald Trump’s so-called reciprocal tariffs were deemed unconstitutional by the Supreme Court, but some sector-specific tariffs will remain in place.
The Supreme Court ruling covered IEEPA tariffs, used for national emergencies ou... |
| 17.02.2026 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00... |
| 11.02.2026 | Will Alphabet’s century bond start a new trend? A brief history | This week Google owner Alphabet raised £1bn in a highly unusual century bond, in a sign of the extreme lengths tech firms are willing to go to to meet the ballooning capital costs of investment in AI.
The 100 year sterling note formed part ... |
| 10.02.2026 | Final Results | Final Results
Tue, Feb 10, 2026 08:00 CET Report this content
10 February 2026
AstraZeneca results: FY and Q4 2025
Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period
Revenue and EPS summary
FY... |
| 06.02.2026 | PDA Introduces the 2026 Board of Directors and Officers | PDA's diverse Board of Directors brings a diverse set of interests, expertise, and experiences.
BETHESDA, Md., Feb. 6, 2026 /PRNewswire-PRWeb/ -- PDA is excited to introduce the all-volunteer 2026 Board of Directors and Officers following f... |
| 06.02.2026 | Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology | CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, Ph... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 05.02.2026 | Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors | Leah Goodman brings a wealth of policy and regulatory experience and is a recognized leader in Australia for advancing scientific discoveries to patient impacts.
CALGARY, AB and BRISBANE, Australia, Feb. 5, 2026 /PRNewswire/ -- Providence T... |
| 04.02.2026 | Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therape... |
| 29.01.2026 | Cellares: $257 Million Series D Closed To Scale Automated Cell Therapy Manufacturing | Cellares has raised $257 million in a Series D financing co-led by investment funds managed by BlackRock and Eclipse, bringing total capital raised to $612 million. The round brings in a slate of new investors, including accounts advised by... |
| 27.01.2026 | Trialbee to Share Vision for the Last Mile of Patient Recruitment with Expert Panel, AI Innovation, and Community Collaboration at SCOPE Summit 2026 | Featuring panelists from BMS, Biogen, and Johnson & Johnson along with the Honey Platform™ and Swedish Fika Time at Booth #706
MALMÖ, Sweden and WILMINGTON, Del., Jan. 27, 2026 /PRNewswire-PRWeb/ -- Trialbee, a global leader in technolo... |
| 26.01.2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| 24.01.2026 | Heart Attack Survivor and Social Media Powerhouse Dr. ShantaQuilette Carter-Williams to Take Center Stage at WomenHeart's 2026 Summit | WomenHeart has announced its 2026 Summit taking place February 1-3 at the Hilton Washington DC National Mall, The Wharf. Heart attack and stroke survivor Dr. ShantaQuilette Carter-Williams, a social media powerhouse with millions of followe... |
| 23.01.2026 | NVIDIA и Eli Lilly вложат $1 млрд в ИИ-лабораторию лекарств | NVIDIA и фармацевтический гигант Eli Lilly объявили о создании совместной ИИ-лаборатории с инвестициями до $1 млрд на пять лет. Лаборатория расположится в Сан-Франциско и объединит биологов и химиков Lilly с инженерами NVIDIA для круглосуто... |
| 22.01.2026 | Telangana (India) Sets Global Ambition with Next-Gen Life Sciences Policy 2026-30 | Positioning Telangana among the world's top five life sciences clusters by 2030
Targets USD 25 billion in investments
Shifts focus from scale-led manufacturing to innovation-driven, value creation
DAVOS, Switzerland, Jan. 22, 2026 /PRNewswi... |
| 21.01.2026 | Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 | BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol ... |
| 20.01.2026 | Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry | Drug pricing, looming patent cliffs, dealmaking and the first year of the second Trump administration dominated conversations at the annual JPMorgan Healthcare Conference in San Francisco.
Top executives from drugmakers of all sizes met wit... |
| 20.01.2026 | Another alliance of health care and AI signals why pharma stocks should be back in favor | - |
| 17.01.2026 | Proxima Secures $80M Seed Round to Redefine Drug Discovery | Proxima, an AI-native biotech firm, secured an $80 million seed funding round. DCVC led the investment. NVentures and other major investors participated. Formerly VantAI, the company now targets proximity therapeutics. It aims to revolution... |
| 14.01.2026 | Oramed And Lifeward Reveal Strategic Deal | Oramed Pharmaceuticals and Lifeward said they have signed binding agreements for a strategic transaction that will move Oramed’s Protein Oral Delivery platform (POD technology) to Lifeward while positioning Oramed as a major shareholder in ... |
| 14.01.2026 | Proxima: $80 Million Raised To Power The Next Generation Of Proximity-Based Medicines | Proxima, the AI-native biotech company developing drug discovery tools and therapeutics for proximity-based medicines, has raised an oversubscribed $80 million seed round and rebranded from VantAI as it sharpens its focus on proximity thera... |
| 13.01.2026 | Proxima Raises $80M in Seed Funding | Proxima (formerly VantAI), a NYC-based AI-native biotech company developing AI-driven drug discovery for proximity therapeutics, raised $80M in Seed funding.
The round was led by DCVC, with participation from NVentures (NVIDIA’s venture cap... |
